MEXICO CITYâ€”Danish insulin maker Novo Nordisk A/S plans to file for regulatory approval for its new anti-obesity drug in Mexico, in a bid to tackle one of the root causes of diabetes in a key market.

The company has targeted Mexico for an early launch of the treatment because of the country's high percentage of overweight people, said Mike Doustdar, senior vice president for international operations at Novo Nordisk.

Seven out...